Châtillon, France — October 29, 2025 — Leads & Copy — DBV Technologies (DBVT) has announced an agreement to sell approximately $30 million in American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The clinical-stage biopharmaceutical company will issue and sell new ordinary shares in the form of ADSs to Artisan Partners Limited Partnership through Citizens Capital Markets, acting as sales agent.
The ATM Issuance involves 10,714,300 new Ordinary Shares (underlying 2,142,860 new ADSs) via a capital increase without preferential subscription rights, at $14.00 per ADS (€2.4063 per Ordinary Share based on a USD/EUR exchange rate of $1.1636 for €1). This represents a 4.89% discount due to trading fluctuations and foreign exchange effects.
The issuance and delivery of the new Ordinary Shares is expected on October 31, 2025. The ADSs will trade on Nasdaq Capital Market, and the new Ordinary Shares on Euronext Paris. Management estimates that the proceeds will extend the company’s cash runway to the end of the fourth quarter of 2026.
Topline results for Viaskin Peanut patch in children 4-7 years old are expected in the fourth quarter of 2025, with a BLA submission anticipated in the first half of 2026. The BLA submission for the 1-3 year-old indication remains on track for the second half of 2026.
Katie Matthews, Investor Contact, DBV Technologies, katie.matthews@dbv-technologies.com
Brett Whelan, Media Contact, DBV Technologies, brett.whelan@dbv-technologies.com
Source: DBV Technologies
